Germline Mutations in BMPR1A/ALK3 Cause a Subset of Cases of Juvenile Polyposis Syndrome and of Cowden and Bannayan-Riley-Ruvalcaba Syndromes*  by Zhou, Xiao-Ping et al.
Am. J. Hum. Genet. 69:704–711, 2001
704
Germline Mutations in BMPR1A/ALK3 Cause a Subset of Cases
of Juvenile Polyposis Syndrome and of Cowden and
Bannayan-Riley-Ruvalcaba Syndromes*
Xiao-Ping Zhou,1,† Kelly Woodford-Richens,2,† Rainer Lehtonen,4,† Keisuke Kurose,1
Micheala Aldred,1 Heather Hampel,1 Virpi Launonen,4 Sanno Virta,4 Robert Pilarski,1
Reijo Salovaara,4,5 Walter F. Bodmer,7 Beth A. Conrad,9 Malcolm Dunlop,10
Shirley V. Hodgson,3 Takeo Iwama,11 Heikki Ja¨rvinen,12 Ilmo Kellokumpu,12
J. C. Kim,13 Barbara Leggett,14 David Markie,15 Jukka-Pekka Mecklin,6 Kay Neale,16
Robin Phillips,16 Juan Piris,8 Paul Rozen,17 Richard S. Houlston,18,‡ Lauri A. Aaltonen,4,‡
Ian P. M. Tomlinson,2,‡ and Charis Eng1,19,‡
1Clinical Cancer Genetics and Human Cancer Genetics Programs, Comprehensive Cancer Center, and the Division of Human Genetics,
Department of Internal Medicine, The Ohio State University, Columbus; 2Molecular and Population Genetics Laboratory, Imperial Cancer
Research Fund, and 3Department of Medical Genetics, United Medical and Dental Schools of Guy’s and St. Thomas’ Hospitals, London;
4Haartman Institute, Department of Medical Genetics, and 5Department of Pathology, University of Helsinki, and 6Second Department of Surgery,
Helsinki Central Hospital, Helsinki; 7Imperial Cancer Research Fund Cancer Immunogenetics Laboratory, Institute of Molecular Medicine,
University of Oxford, and 8Department of Pathology, John Radcliffe Hospital, Oxford; 9United Hospitals, Saint Paul; 10Medical Research Council
Human Genetics Unit, Western General Hospital, Edinburgh; 11Centre for Polyposis and Intestinal Diseases, Tokyo; 12Department of Surgery,
Jyva¨skyla¨ Central Hospital, Jyva¨skyla¨, Finland; 13Department of Pediatrics, University of Ulsan College of Medicine and Asan Institute, Seoul;
14Queensland Institute of Medical Research, Royal Brisbane Hospital, Herston, Brisbane; 15Molecular Genetics Laboratory, Pathology Department,
Dunedin School of Medicine, Dunedin, New Zealand; 16Polyposis Registry, St. Mark’s Hospital, Harrow, Middlesex, England; 17Department of
Gastroenterology, University of Tel Aviv, Tel Aviv; 18Section of Cancer Genetics, Institute of Cancer Research, Sutton, Surrey, England; and
19Cancer Research Campaign Human Cancer Genetics Research Group, University of Cambridge, Cambridge
Juvenile polyposis syndrome (JPS) is an inherited hamartomatous-polyposis syndrome with a risk for colon cancer.
JPS is a clinical diagnosis by exclusion, and, before susceptibility genes were identified, JPS could easily be confused
with other inherited hamartoma syndromes, such as Bannayan-Riley-Ruvalcaba syndrome (BRRS) and Cowden
syndrome (CS). Germline mutations of MADH4 (SMAD4) have been described in a variable number of probands
with JPS. A series of familial and isolated European probands withoutMADH4mutations were analyzed for germline
mutations in BMPR1A, a member of the transforming growth-factor b–receptor superfamily, upstream from the
SMAD pathway. Overall, 10 (38%) probands were found to have germline BMPR1A mutations, 8 of which resulted
in truncated receptors and 2 of which resulted in missense alterations (C124R and C376Y). Almost all available
component tumors frommutation-positive cases showed loss of heterozygosity (LOH) in theBMPR1A region,whereas
those from mutation-negative cases did not. One proband with CS/CS-like phenotype was also found to have a
germline BMPR1A missense mutation (A338D). Thus, germline BMPR1A mutations cause a significant proportion
of cases of JPS and might define a small subset of cases of CS/BRRS with specific colonic phenotype.
Introduction
The major hamartomatous-polyposis syndromes com-
prise juvenile polyposis syndrome (JPS [MIM 174900]),
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Peutz-Jeghers syndrome (PJS [MIM 175200]), Cowden
syndrome (CS [MIM 158350]), and Bannayan-Riley-
Ruvalcaba syndrome (BRRS [MIM 153480]). Whereas
CS and a subset of BRRS are allelic (Marsh et al. 1997a,
1999), current evidence suggests that CS and BRRS are
genetically distinct from JPS and PJS (for reviews, see
Eng and Ji 1998; Eng and Parsons 2001). PJS is an
autosomal dominant disorder characterized by peri-
oral pigmented spots, hamartomatous polyposis, and a
risk for colon and breast cancers (Boardman et al. 1998;
for review, see Eng et al. 2001). Germline mutations of
the nuclear serine-threonine–kinase gene LKB1/STK11
cause most cases of PJS (Hemminki et al. 1998; Jenne
et al. 1998). CS is a poorly recognized autosomal dom-
inant cancer syndrome characterized by multiple ha-
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Figure 1 Spectrum of germline BMPR1A mutations in 14 probands with JPS and in 1 family with CS/BRRS. The exons are depicted by the
numbered boxes at the top, and the domains of the receptor are depicted below. Signal peptide (SP), transmembrane domain (TM), ATP-binding
domain (ATP), extracellular domain (dotted bar), and kinase domain (black bar) are shown. Black squares represent the four families’ mutations
published by Howe et al. (2001).
martomas and by a high risk for breast, thyroid, and
endometrial cancers (Eng 2000). Although gastrointes-
tinal hamartomatous polyposis can be documented if
systematically searched for (Weber et al. 1998), the pol-
yps are rarely symptomatic in CS, in contrast to the other
three syndromes. BRRS is a congenital disorder char-
acterized by macrocephaly, lipomatosis, thyroid prob-
lems, and pigmented macules on the glans penis in males
(Gorlin et al. 1992); in BRRS, gastrointestinal hamar-
tomatous polyposis can be quite prominent and symp-
tomatic (Tsuchiya et al. 1998). Germline mutations in
the tumor-suppressor gene PTEN cause 80% of cases
of classic CS and 60% of cases of BRRS (Marsh et al.
1998b, 1999). There is little, if any, linkage evidence of
genetic heterogeneity in CS (Nelen et al. 1996). The ex-
tent of genetic heterogeneity in BRRS is unknown. Clin-
ical diagnosis of JPS is by exclusion, and JPS is char-
acterized by gastrointestinal hamartomatous polyposis
and by a risk for gastrointestinal cancers (for review, see
Eng et al. 2001). Germline mutations in MADH4
(SMAD4) have been described in a proportion of cases
of JPS (Howe et al. 1998). From a nonsystematic sur-
vey of North American probands with JPS, it was esti-
mated that ∼35–60% of cases of JPS would harbor
germline MADH4 mutations (Howe et al. 1998); how-
ever, 3%–28% (weighted average 15%) of cases of JPS
originating mainly from Europe have been found to
carry MADH4 mutations (Houlston et al. 1998; Friedl
et al. 1999; Roth et al. 1999; Woodford-Richens et al.
2000a, and in press). Thus far, genes encoding several
other SMADs have not been found to be associated with
JPS (Bevan et al. 1999; Roth et al. 1999). Recently, germ-
line truncating mutations in BMPR1A/ALK3/SKR5
were described in four of four families segregating JPS
(Howe et al. 2001). BMPR1A, on 10q21-q22, encodes
a bone morphogenic-protein–receptor serine-threonine
kinase that belongs to the transforming growth-factor b
(TGFB)–receptor SMAD superfamily (for reviews, see
Massague´ 2000; Eng 2001). Members of the TGFB-
receptor superfamily can homo-oligomerize or hetero-
oligomerize.
We have examined BMPR1A for germline mutations,
in a cohort of familial and sporadic cases of JPS, with
the hypotheses that this mainly European cohort with
a relatively low MADH4-mutation frequency would
have a high frequency of BMPR1A mutations with a
distinct mutational spectrum. Furthermore, because of
the location of this gene in proximity to PTEN (Dahia
et al. 2000) and, perhaps, because of its function, it also
became a good candidate gene for susceptibility in
PTEN-mutation–negative cases of CS and of BRRS.
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Families, Material, and Methods
Families
Eighteen unrelated families with JPS and seven isolated
cases of JPS were ascertained by clinical criteria described
elsewhere (Marsh et al. 1997b) and were already known
not to carry germline MADH4 mutations. Although all
families and individuals met the diagnostic criteria for JPS,
some affected individuals had developed other tumors
(table 1)—predominantly, colorectal adenomas and/or
cancer—as is common in this condition (Woodford-Rich-
ens et al. 2000a). Twenty-one probands with CS/BRRS
or CS/BRRS-like phenotype without germline PTEN mu-
tations were ascertained by the revised operational di-
agnostic criteria of the International Cowden Consortium
(Eng 2000) and by criteria described elsewhere (Marsh et
al. 1998a, 1999). Probands and families with CS/BRRS-
like phenotype have component features of CS/BRRS but
do not meet the operational diagnostic criteria set forth
by the International Cowden Consortium. All specimens
were collected and analyzed, after informed consent was
obtained, under protocols approved by each institution’s
Human Subjects Protection Committees.
Mutation Analysis
Genomic DNA was extracted from peripheral leuko-
cytes, by standard protocols (Mathew et al. 1987). As
template, 20–100 ng of DNA was used for 35 cycles (94C
for 1 min, 55C for 1 min, and 72C for 1 min, after a
hot start) of PCR amplification of each of the 11 coding
exons (thus, ALK3E3 corresponds to exon 1, etc.) and
flanking intronic regions of BMPR1A, by use of the fol-
lowing primers: ALKE3F (5′-TCCAAAATTCAGTTGT-
ATTCC-3′), ALKE3R (5′-CACATACATTACTAAAAT-
GAACACTG-3′), ALKE4F (5′-GTCACGAAACAATG-
AGCTTT-3′), ALKE4R (5′-TTAAGAAGGGCTGCAT-
AAAA-3′), ALKE5F (5′-CATTCAGACTCAAATTTCG-
TT-3′), ALKE5R (5′-TCTCATGGGTCCCAAATTA-3′),
ALKE6F (5′-CCAAACCATTTCTAATTTTATCA-3′),
ALKE6R (5′-CATGCTCCGACTTTTCTC-3′), ALKE7F
(5′-CCAGGCTACCTAGAATTGAA-3′), ALKE7R (5′-
AACAGCGGTTGACATCTAAT-3′), ALKE8F (5′-CCT-
CAAGGTTTTTCTTAGGG-3′), ALKE8R (5′-TCAAC-
ACACCATTCATGTCT-3′), ALKE9F (5′-TCATCAAG-
AGCTCAAACCTT-3′), ALKE9R (5′-ACCTCACTAGC-
CTTGTCAAA-3′), ALKE10F (5′-CCCTAGCCTATCT-
CTGATGA-3′), ALKE10R (5′-AACAGTGGGGCAAA-
GAAC-3′), ALKE11F (5′-TATTTTATTTTTGGCCCT-
CA-3′), ALKE11R (5′-TGATGAGTAAATCAACATAA-
TCAG-3′), ALKE12F (5′-ATTTTTGTGCCCATGTTT-
T-3′), ALKE12R (5′-AATCACTTCTTCAGGGGACT-
3′), ALKE13F (5′-ACTCAGTCCCCTGAAGAAGT-3′),
and ALKE13R (5′-CTAGAGTTTCTCCTCCGATG-3′).
The amplicons were gel- and column-purified and then
were subjected to semiautomated PCR-based sequence
analysis by an ABI-377a or a Perkin-Elmer 3700, as
described elsewhere (Mutter et al. 2000).
Loss of Heterozygosity (LOH) Analysis
Available component tumors from BMPR1A-muta-
tion–positive and BMPR1A-mutation–negative cases
of JPS were subjected to LOH analysis with markers
ALK3ca, ALK3ggaa, and D10S573, by techniques de-
scribed elsewhere (Marsh et al. 1998c; Woodford-Rich-
ens et al. 2000b). Two component tumors from pro-
band JP8/1 (table 1) was analyzed by sequencing of the
amplicon containing the germline mutation, to examine
allelic contribution.
Reverse-Transcriptase PCR (RT-PCR) Analysis
To assess the putative splice-site mutation in proband
JP8/1, RNA was extracted from her component tumors,
a Wilms tumor (table 1), and a colon carcinoma, and
cDNA was synthesized. RT-PCR was performed using
the primers 5′-GCATAGGTCAAAGCTGTTTGG-3′ and
5′-GCAAGGTATCCTCTGGTGCT-3′, with AmpliTaq
Gold (Perkin-Elmer) at and annealing temperature of
60C. Amplicons were fractionated through 2% agarose,
were stained with ethidium bromide, and then were vi-
sualized with UV trans-illumination. Any aberrant bands
noted on the gel were cut out of low-melting-point aga-
rose, were gel- and column-purified, and then were sub-
jected to sequence analysis.
Results
All 11 coding exons, splice junctions, and flanking in-
tronic regions of BMPR1A were examined in 18 unre-
lated MADH4-mutation–negative families with JPS and
in seven unrelated MADH4-mutation–negative individ-
uals with isolated JPS. All available polyps from these
cases showed no loss of SMAD4 expression. Overall, of
25 unrelated probands with JPS, 10 (40%) were found
to have germline BMPR1A mutations (fig. 1): 6 (33%)
of the 18 familial cases and 4 (57%) of the 7 isolated
cases had germline mutations. In the mutation-positive
familial cases in which samples from family members
were available, the respective mutations were shown to
segregate with affected status (data not shown)
Of the 10 germline BMPR1A mutations found in pro-
bands with JPS, all except 2 were nonsense, frameshift,
or splice-site mutations predicted to result in truncated
receptors (fig. 1). The missense mutations found in cases
of JPS were examined in cohorts of 50 race-matched
normal controls. None of the 100 normal control chro-
mosomes were found to carry these missense muta-
tions; furthermore, in the familial cases of JPS with
C376Y, this mutation was found to segregate with dis-
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Figure 2 LOH analysis with microsatellite markers alk3ca (A)
and alk3ggaa (B), which lie in proximity to BMPR1A (see text), and
genomic DNA templates from family JP7/19, whose members harbor a
germline missense mutation, generated from peripheral blood leukocytes
(i), from villous adenoma (ii), from two villous adenomas with adeno-
carcinomatous components (iii and iv), and from normal tissue origi-
nating from the same archival section as one of the villous adenomas
with adenocarcinoma (v).
ease. Loss of the wild-type allele in three component tu-
mors—all of which were villous adenomas and two of
which also had adenocarcinomatous components—from
an affected family member was also demonstrated (fig.
2). The splice-site mutation IVS1-3crg was shown to
result in skipping of exon 1, and the component tumor
(a Wilms tumor; table 1) from the proband had loss of
the wild-type allele. A colorectal carcinoma from the pro-
band with the IVS1 splice mutation did not show LOH.
Thus, of five component tumors from BMPR1A-muta-
tion–positive individuals, four were found to have loss
of the wild-type allele. In contrast, 24 component tumors
from 13 familial and isolated cases without germline
BMPR1Amutations showed no LOH in that region (data
not shown).
Although limited because of small sample size, geno-
type-phenotype associations were examined, especially
those with respect to cardiac anomalies or to head/fa-
cial features (table 1 and fig. 1). Both among the 10
BMPR1A-mutation–positive families and among the 15
BMPR1A-mutation–negative families, 2 had cardiac
anomalies; because of the limited size of sample, these
were not considered statistically different. Similarly, there
appeared to be no difference between the numbers of
mutation-positive and mutation-negative families and in-
dividuals with macrocephaly or hypertelorism. Although
there were only two probands/families with mutations as
well as with the clinical features of hypertelorism and
macrocephaly, both of these mutations—IVS5-1grt
(SM316) and c.665insT (FT)—occurred in the juxta-
transmembrane domain (fig. 1).
Of 21 unrelated probands with CS/BRRS, without
germline PTEN mutations, 1 was found to have a germ-
line missense mutation, A338D, in exon 8 of BMPR1A.
This missense alteration was not observed among 172
race-matched, geographically matched control chro-
mosomes. Interestingly, the proband had only colonic
polyposis, which comprised hamartomatous and ade-
nomatous polyps and began at the age of 16 years, and
lipomas. Her family history, however, comprised indi-
viduals with breast cancer, with renal-cell carcinoma,
with brain tumor(s), and with melanoma. Taken to-
gether, these features constitute the minimum criteria
(i.e., one major and three minor) for the diagnosis of
CS (Eng 2000). It is acknowledged that the diagnosis
of CS in this family barely met the minimum Interna-
tional Cowden Consortium diagnostic criteria, and
some clinicians might consider this family to have a CS-
like phenotype. None of the other probands with CS/
BRRS or CS/BRRS-like phenotype were found to have
BMPR1A mutations.
Discussion
In this cohort of familial and isolated cases of JPS who
are MADH4-mutation–negative and who originate
mainly from Europe, 40% have been found to harbor
germline BMPR1A/ALK3 mutations. Thus, among Eu-
ropean cases of JPS, MADH4 mutations account for
28% of cases and BMPR1A mutations account for
40%. No systematic survey of cases of JPS originating
in the United States has been performed yet, and it thus
is unknown what proportion cases of JPS is due to
BMPR1A mutations. Nonetheless, at least one other
JPS-susceptibility gene should exist.
Overall, to date, 14 different germline BMPR1A mu-
tations have been described in probands with JPS—10
in patients from this study and the 4 in U.S. kindreds
described elsewhere (Howe et al. 2001). Of these germ-
line BMPR1A mutations, 9 (64%) are located within
exons 6–8 (exon 1 is the first coding exon; there are
two other noncoding exons 5′ of exon 1), encoding part
of the intracellular domain of the receptor (fig. 1), and,
of these 9 mutations, 8 have occurred in the N-terminal
142 amino acids of the kinase domain, half of which
are in close proximity to the ATP-binding site. There
are no mutations located in or beyond the C-terminal
half of the kinase domain. Interestingly, the two pro-
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bands with mutations occurring in exons 5 and 6 both
have macrocephaly and hypertelorism.
All but one of the nine mutations in the cytoplasmic
domain are predicted to result in truncated receptors
(fig. 1). The truncations all leave an intact transmem-
brane domain, such that the mutant receptors could be
processed, to reach the plasma membrane, but are lack-
ing all or part of the kinase domain. If the mutations
in the cytoplasmic domain do result in truncated recep-
tors, then these truncated receptors might be expected
to bind ligand, but no signaling could occur. Thus, these
intracellular-domain mutations might be predicted to
act via dominant negative mechanisms. Family JP7/19
has a missense mutation in the middle of the kinase
domain, C376Y. Residue 376 lies within the kinase do-
main, in close proximity to the active site, and is highly
conserved among species—fromCaenorhabditis elegans
to mouse and rat. Four of the five mutations in the
extracellular domain are predicted to result in truncated
receptors. However, unlike the truncations in the cy-
toplasmic domain, two of the truncations would result
in the lack of all or part of the signal peptide. The third
truncation, S44X, results in a very short peptide without
a transmembrane domain. Cysteine 124 lies in the cys-
teine-rich domain, which characterizes receptor kinases
and is highly conserved across the TGFB family of type
I and type II receptors, as well as across species (Kirsch
et al. 2000). The ectodomain of BMPR1A has six in-
tramolecular disulfide bridges between pairs of cyste-
ines, which conformationally allows for BMP2 binding
(Kirsch et al. 2000). Cysteine 124 is part of disulfide
bond 4, and between the two cysteines forming this
disulfide bridge lie nine key residues, which form part
of the ligand-binding epitope. Loss of the sulfhydryl
group at residue 124, as would be the case for this
mutation, would therefore result in severe conforma-
tional alterations and in loss of the ability to bind ligand.
The splice mutation IVS5-1grt would be predicted to
result in a receptor without a transmembrane domain.
Thus, in general, extracellular-domain germline muta-
tions—whether truncating or missense—together with
the somatic second hit—as evidenced by LOH in the
BMPR1A region in the majority of component tumors,
both benign and malignant—might result in physical or
functional lack of receptor. These observations contrast
with those of Howe et al. (2001), who failed to detect
LOH in component tumors from mutation-positive
families. Our data demonstrating that BMPR1A be-
haves in accordance with the Knudson two-hit theory
strongly suggest that BMPR1A encodes a tumor sup-
pressor and likely also plays a gatekeeping function
(Kinzler and Vogelstein 1998), much like SMAD4 itself
(Woodford-Richens et al. 2000b).
Although the sample size is small, it would appear
that, among the nine cytoplasmic-domain mutations,
seven have occurred in familial cases of JPS whereas
only two have occurred in isolated cases of JPS. In con-
trast, of the four extracellular-domain mutations, two
occur in familial cases and three occur in isolated cases.
Because of the small sample sizes of each subset, no
statistical significance can be inferred. However, an in-
teresting hypothesis to test in the future is thatBMPR1A
mutations that occur in the cytoplasmic domain and
that are predicted to be dominant negative are associ-
ated with higher penetrance and with familial trans-
mission. Because we have demonstrated LOH in com-
ponent tumors from mutation-positive individuals—
and if this hypothesis is correct—then the dominant-
negative effect must act against other TGFB-recep-
tor–family partners with which BMPR1A normally het-
ero-oligomerizes. Extracellular mutations that mainly
result in haploinsufficiency, on the other hand, are as-
sociated equally with isolated and familial cases.
Because CS and BRRS lie within a single spectrum
(Marsh et al. 1999), we chose to examine probands with
CS/BRRS and CS/BRRS-like phenotype as one group.
Only one such proband with CS/CS-like phenotype was
found to harbor a BMPR1A mutation—specifically,
A338D. This missense mutation occurs in the kinase
domain—more specifically, immediately downstream of
the kinase catalytic core—and in a residue that is highly
conserved across species, from C. elegans to mouse and
rat. Thus, if an acidic hydrophilic residue (aspartate)
were substituted for a neutral nonpolar residue (ala-
nine), the kinase catalytic core would be predicted to
be disrupted. Although ligand binding might still be
possible, this mutation could be predicted to result ei-
ther in a loss of substrate specificity or in a receptor
that might not be able to bind substrate.
Despite some initial confusion that germline PTEN
mutations might be associated with rare cases of JPS
(Olschwang et al. 1998), over the course of the past 4
years of clinical and molecular-epidemiologic analyses,
it has become obvious that the presence of germline
PTEN mutations defines CS and BRRS, regardless of
the manner of clinical presentation (Eng and Ji 1998;
Kurose et al. 1999; Marsh et al. 1999). This is germane
for clinical cancer genetic practice, because the presence
of PTEN mutations implies organ-specific surveillance
of the patient and of his or her family. On the other
hand, detection of a MADH4 or a BMPR1A mutation
should be considered diagnostic of JPS. In our opinion,
families with CS/BRRS or CS/BRRS-like phenotype
with BMPR1A mutations must therefore, on the basis
of molecular data, be reclassified as having JPS.
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